Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from McKesson ( (MCK) ) is now available.
On September 23, 2025, McKesson Corporation hosted its Investor Day, unveiling updated Fiscal 2026 guidance and long-term financial targets. The event highlighted the company’s strategic priorities, including strengthening North American pharmaceutical distribution, expanding oncology and biopharma services, and optimizing its portfolio. McKesson also introduced a new organizational structure to accelerate growth and enhance shareholder value, raising its Fiscal 2026 Adjusted Earnings per Diluted Share guidance and updating long-term growth targets, reflecting its strong market positioning and operational momentum.
The most recent analyst rating on (MCK) stock is a Buy with a $810.00 price target. To see the full list of analyst forecasts on McKesson stock, see the MCK Stock Forecast page.
Spark’s Take on MCK Stock
According to Spark, TipRanks’ AI Analyst, MCK is a Neutral.
McKesson’s overall stock score is driven by strong earnings call results and solid financial performance, particularly in revenue growth and cash flow generation. However, high leverage and low profit margins present risks. The technical analysis suggests a neutral to slightly positive trend, while the valuation indicates potential overvaluation concerns.
To see Spark’s full report on MCK stock, click here.
More about McKesson
McKesson Corporation operates in the healthcare industry, focusing on pharmaceutical distribution, oncology, multispecialty, and biopharma services. The company is known for its strategic growth initiatives and aims to enhance patient health outcomes through its differentiated assets and capabilities.
Average Trading Volume: 758,683
Technical Sentiment Signal: Buy
Current Market Cap: $86.7B
For an in-depth examination of MCK stock, go to TipRanks’ Overview page.